A New Diterpene and Anti-inflammatory Sesquiterpene Lactones from Sigesbeckia orientalis
- 21 September 2020
- journal article
- research article
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 86 (15), 1108-1117
- https://doi.org/10.1055/a-1232-6869
Abstract
Sigesbeckia orientalis, more commonly referred to as Herba Sigesbeckiae or Xi Xian Cao in traditional Chinese medicine and hy thiêm in traditional Vietnamese medicine, is used in China and Vietnam to treat inflammatory diseases such as arthritis, rheumatism, and joint pain. In initial investigations, the dichloromethane extract from the aerial parts of S. orientalis showed distinct inhibitory effects on the release of interleukin-8 in human neutrophils. Therefore, the purpose of the present study was the phytochemical investigation of the bioactive dichloromethane extract and the in vitro analysis of the effects of the isolated compounds on interleukin-8, interleukin-1β, tumor necrosis factor-α, and monocyte chemoattractant protein 1 release, and surface expression of adhesion molecules (CD11a, CD11b, and CD62L) in lipopolysaccharide-stimulated human neutrophils to identify the active principle(s). The separation of the bioactive dichloromethane extract using various chromatographic techniques led to the isolation of nine compounds. Their chemical structures were elucidated from nuclear magnetic resonance and mass spectrometry data. One diterpene, 17(13 → 14)-abeo-ent-3S*,13S*,16-trihydroxystrob-8(15)-ene, was identified as a new natural product. Three germacranolide sesquiterpene lactones inhibited interleukin-8 production with IC50 values between 1.6 and 6.3 µM, respectively, and tumor necrosis factor-α production with IC50 values between 0.9 and 3.3 µM, respectively. Furthermore, they significantly inhibited interleukin-1β and monocyte chemoattractant protein 1 production and diminished the effects of lipopolysaccharide on the surface expression of the adhesion molecules CD11a, CD11b, and CD62L. These findings support the traditional use of S. orientalis in the treatment of inflammatory diseases. * Dedicated to Professor Dr. Wolfgang Kubelka on the occasion of his 85th birthday. Received: 15 January 2020 Accepted after revision: 27 July 2020 Publication Date: 21 September 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Stuttgart · New YorkKeywords
Funding Information
- OeAD-GmbH (PL13/2015)
This publication has 34 references indexed in Scilit:
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- In Vitro Antiinflammatory Activity of a New Sesquiterpene Lactone Isolated from Siegesbeckia glabrescensPhytotherapy Research, 2011
- Quercetin Reduces Neutrophil Recruitment Induced by CXCL8, LTB4, and fMLP: Inhibition of Actin PolymerizationJournal of Natural Products, 2011
- Recent Advances in Underlying Pathologies Provide Insight into Interleukin-8 Expression-Mediated Inflammation and AngiogenesisInternational Journal of Inflammation, 2011
- Immunosuppressive Activity of the Ethanol Extract of Siegesbeckia orientalis on the Immune Responses to Ovalbumin in MiceChemistry & Biodiversity, 2006
- ent-Pimarane-Type Diterpenoids from Siegesbeckia orientalis L.CHEMICAL & PHARMACEUTICAL BULLETIN, 2005
- Helenalin, an Anti-Inflammatory Sesquiterpene Lactone from Arnica, Selectively Inhibits Transcription Factor NF-κBBiological Chemistry, 1997
- Interleukin‐8, a chemotactic and inflammatory cytokineFEBS Letters, 1992
- Melampolides and other constituents from Furinea leptolobaPhytochemistry, 1991
- A new melampolide from Sigesbeckia orientalisPhytochemistry, 1979